Dmitry Balyasny’s Aimmune Therapeutics AIMT Stock Holding History

Dmitry Balyasny’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-388,384	Closed	-$13.4M	–	1879
2020 Q3	$13.4M	Buy	388,384 +153,529	+65%	+$3.27M	0.1%	306
2020 Q2	$3.92M	Sell	234,855 -174,721	-43%	-$2.97M	0.03%	580
2020 Q1	$5.91M	Buy	409,576 +196,274	+92%	+$5.02M	0.07%	365
2019 Q4	$7.14M	Sell	213,302 -460,465	-68%	-$12.9M	0.04%	513
2019 Q3	$14.1M	Buy	673,767 +508,089	+307%	+$10.4M	0.1%	312
2019 Q2	$3.45M	Buy	165,678 +133,765	+419%	+$2.75M	0.02%	717
2019 Q1	$713K	Sell	31,913 -344,846	-92%	-$8.12M	﹤0.01%	1104
2018 Q4	$9.01M	Sell	376,759 -26,280	-7%	-$680K	0.07%	375
2018 Q3	$11M	Buy	403,039 +38,227	+10%	+$1.08M	0.05%	458
2018 Q2	$9.81M	Sell	364,812 -352,063	-49%	-$10.8M	0.04%	493
2018 Q1	$22.8M	Buy	+716,875	New	+$25.2M	0.1%	299

Dmitry Balyasny's AIMT Position: Q4 2020 in Review

Dmitry Balyasny sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 388,384 shares — an estimated $13.4M sold.

Dmitry Balyasny first reported a position in AIMT in Q1 2018 and held it in 11 quarters. The position peaked at $22.8M in Q1 2018. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Dmitry Balyasny reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Dmitry Balyasny sold 388,384 Aimmune Therapeutics shares in Q4 2020, an estimated $13.4M.
Dmitry Balyasny first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 11 quarters.
Dmitry Balyasny's Aimmune Therapeutics position peaked at $22.8M in Q1 2018.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Balyasny Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.